Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.
They Cost Millions. How Payers Might Manage Those Astronomical Gene Therapy Bills
Paying in installments with adjustments according to how well a gene therapy works is one way payers are coping with therapies with list prices in millions of dollars.
Swarup S Swaminathan, M.D., of University of Miami Discusses Social Vulnerability and Glaucoma
By identifying patients with glaucoma who are socially vulnerable, clinicians might intervene sooner and prevent the worsening of visual impairment, he said.
PDT Studies: The Positives, the Shortcomings — and Getting the Good Parts ‘Packaged Together’
The corresponding author of a study published in Health Affairs of the research supporting 20 FDA-authorized prescription digital therapeutics (PDTs) sees some positives but also an overall lack of rigor and the need for at least one high-quality clinical trial for each PDT.
Why Study the Studies of PDTs?
Prescription digital therapeutics (PDTs) have great potential for treating a wide range of conditions, so studying the quality of the evidence supporting their efficacy and safety is important, says the corresponding author of a study on PDTS published in this month's Health Affairs.
Studies Supporting PDTs Often Short on Rigor, Inclusivity, Research Finds
There were some positive findings. But of the 20 FDA-authorized prescription digital therapeutics (PDTs) identified by researchers, only two met all the criteria for high-quality research. The results were published in Health Affairs.
ICD-10 Codes Don't Tell the Full Story About Heart Failure | AHA Scientific Sessions
Ejection fraction is a key factor in how clinicians diagnose, classify and treat heart failure. But you might not know it if you depended solely on ICD-10 codes.
Has Elevated Lipoprotein(a), the Elusive Cardiovascular Risk Factor, Met Its Match? | AHA Scientific Sessions
Researchers reported positive results at the AHA meeting today from a small, 48-patient study of lepodisiran, a short interfering RNA therapy designed to reduce lipoprotein(a) levels.
A First: CRISPR-based Gene Editing Therapy for LDL Cholesterol Lowering In Humans | AHA Scientific Sessions
Ten patients have been treated with the CRISPR-based gene therapy, the drug developer's chief scientific officer announced today, and high doses have had the intended effect of lowering LDL cholesterol. One study volunteer died five weeks after the infusion from cardiac arrest, but the company says the death was unrelated to the therapy and no changes were made to the study.
It's Not Just About Cardiovascular Disease. Lowering Blood Pressure Reduces All-Cause Dementia | AHA Scientific Sessions
A study that randomized villages in China to an intensive blood pressure-lowering program or usual care showed a 15% decrease in all-cause dementia from the program.
Angioplasty For Stable Angina On Par With Antianginal Medications, Say ORBITA-2 Investigators | AHA Scientific Sessions
Positive findings from their placebo-controlled trial show that angioplasty is an evidence-based, first-line treatment for patients with stable angina and that they needn't necessarily be treated first with antianginal medications, say the ORBITA-2 investigators.
Wegovy Cuts Risk of Serious Cardiovascular Events By 20% in Those Without Diabetes, Study Finds | AHA Scientific Sessions
Results from the SELECT trial presented at the American Heart Association Scientific Sessions meeting suggest that the GLP-1 inhibitor may have a role in cardiovascular disease protection beyond weight loss and diabetes.
Payers Warm To Prescription Digital Therapeutics But Want Real-World Evidence, Pilot Projects and Alternative Payment Contracts, Survey Shows
Otsuka American Pharmaceutical is tracking payer practices and attitudes about digital therapeutics with a series of four surveys.
Details on 5 Cases of Complications From Syfovre Injections | AAO 2023
One patient had complications that resulted in no light perception — effectively, blindness — in the the treated eye.
PHOTON Study of 8-mg Eylea Suggests Some Patients Could Be Treated Just Two Times a Year | AAO 2023
Approximately one-third of the patients assigned to 16-week intervals of 8-mg formulation of Eylea changed to a 24-week interval during the second year of. the study, according results presented at the annual meeting of the American Academy of Ophthalmology. The PHOTON study enrolled people with diabetic macular edema.
Teleophthalmology: One Way To Help Span the Healthcare Disparity Divide | AAO 2023
Albert S. Khouri, M.D., a professor of ophthalmology at the Rutgers New Jersey Medical School, discusses teleophthalmology’s role in outreach efforts and improving ophthalmic care in the emergency room.
Ophthalmology and Telehealth, A Suitable Match | AAO 2023
Albert S. Khouri, M.D., says ophthalmic care lends itself to telehealth because it is image based. As with many other areas of medicine, the COVID-19 pandemic accelerated adoption.
Suprachoroidal Space Shows Promise As Location for Delivering Treatment | AAO 2023
Delivering medication in the suprachoroidal space would be less invasive than intravitreal injections used to deliver many eye treatments.
Private Equity, Boon or Bane, for Retina Specialists? | AAO 2023
Private equity (PE) can bring capital investment to retina specialty practices and significantly increase the incomes of the physicians, said a proponent during a debate on private equity at the AAO meeting. The retina specialist arguing against PE said physicians lose control of their practices and the loyalty of their staff and that profits get prioritized over patients.
Syfovre Complications Discussed in Late-Breakers Session | AAO 2023
Suber S. Huang, M.D., MBA, a panelist for a session about late-breaking research, said the presentation about Syfovre complications among patients treated at the Wolfe Eye Clinic in Iowa is one of the most important of this year's annual meeting. Five patients experienced complications from the new drug for geographic atrophy.
Positive Results for Higher, Less Frequent Dosing of Eylea | AAO 2023
Results at 96 weeks were similar to those at 48 weeks. The FDA approved the 8-mg formulation of Eylea (aflibercept) in August 2023.
Hospitals to Get $9B in 340B Money
About 1,700 hospitals will receive lump sums after the Supreme Court ruled that CMS was wrong when it cut reimbursement rates for Part B drugs.
Phase 3 Trial Points to Successful Treatment of Itch-Causing Condition — and Type 2 Inflammation as a Culprit
Nemolizumab quelled the itching caused by prurigo nodularis, a rare skin condition. By inhibiting interleukin-31, the experimental drug seems to have a downstream effect on other interleukins secreted during type 2 inflammation.
Gremminger Succeeding Thompson as Head of National Alliance of Healthcare Purchaser Coalitions
Shawn Gremminger, M.P.P., has worked for a variety of healthcare organizations in legislative affairs and policy roles.
Antivirals After Liver Resection for HBV-Associated Hepatocellular Carcinoma: Which Is Better, Tenofovir vs. Entecavir?
In Type 2 Inflammation, an Unexpected Relationship Between Itchiness and Inflammation
When interleukin (IL)-31 stimulates nerves that create itchiness it may also have a downstream effect that tempers inflammatory processes, according to mouse model research done by investigators at the University of California, San Francisco.
AI Improving Healthcare Efficiency, the Evolution of VBC, Reducing Healthcare Waste and More With William Shrank of Andreessen Horowitz
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, had a discussion with William Shrank, M.D., a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California, about how artificial intelligence's role is improving healthcare, where we are today with value-based care and the ongoing efforts of reducing waste in the healthcare space for this episode of the "What's on Your Mind" podcast series.
Internet-based CBT Helps MS Patients With Depression Become Less Depressed
Results of a randomized trial reported in The Lancet Digital Health suggest a role for internet-based cognitive behavioral therapy, but many of the study volunteers were left with symptoms that would classify them as having major depressive disorder.
How Prime Therapeutics Tugged on the Reins of the Galloping GLP-1 Spend | AMCP Nexus 2023
The Minnesota-based pharmacy benefit manager says a program that resulted in patients switching from two incretin therapy prescriptions to one yielded $7,500 in savings per patient and a total of $3.5 million.
Outcomes From Horizon BCBS of New Jersey Oncology Home Infusion Program | AMCP Nexus 2023
The program yielded savings of $25,000 per patient in its pilot phase but is not expected to produce savings as a routine offering because reimbursement for home infusion was matched to reimbursement at a facility. Horizon executive Timothy O’Shea, Pharm.D., M.S., says cost savings were a “secondary outcome” of the program and noted the high patient satisfaction.
Horizon BCBS of New Jersey Launches Oncology Home Infusion Program | AMCP Nexus 2023
Just over 160 patients have participated in the insurer's oncology home infusion program since it started in late 2020. Patient satisfaction is high, according to Horizon officials, who are looking to expand the program with other providers in its market and to include more drugs that patients could be treated with at home.
2 Clarke Drive Cranbury, NJ 08512